Free shipping on all orders over $ 500

Istradefylline

Cat. No. M3188

All AbMole products are for research use only, cannot be used for human consumption.

Istradefylline Structure
Synonym:

KW-6002

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 50  USD50 In stock
5mg USD 35  USD35 In stock
10mg USD 55  USD55 In stock
50mg USD 100  USD100 In stock
100mg USD 155  USD155 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Istradefylline (KW-6002) is a potent, selective and orally active adenosine A2A receptor (A2AR) antagonist with Ki of 2.2 nM. Istradefylline binds to A1 receptor, A2A receptor, and A3 receptor in human with Kis of >287 nM, 9.12 nM, and >681 nM, respectively, 50.9 nM and 1.57 nM for A1 receptor and A2A receptor in rat, 105.02 nM and 1.87 nM for A1 receptor and A2A receptor in mouse, respectively.

Oral administration of Istradefylline improves motor disability in MPTP-treated parkinsonian marmosets in a dose-dependent manner without provoking dyskinesia. Istradefylline treatment potentiates rotational behavior induced by dopaminergic drugs in hemi-Parkinsonian rats. Istradefylline treatment alone causes an approximately 20% reduction in the striatal levels of preproenkephalin mRNA, whereas neither the coadministration of KW-6002 and L-DOPA nor L-DOPA alone significantly alters the expression of this transcript in the dopamine-denervated striatum.

Protocol (for reference only)
Cell Experiment
Cell lines
Preparation method
Concentrations
Incubation time
Animal Experiment
Animal models Common marmosets (Callithrix jacchus) with MPTP treatment
Formulation Suspended in 0.3% Tween-80 and 10% sucrose solution
Dosages 10 mg/kg
Administration Oral gavage
Chemical Information
Molecular Weight 384.43
Formula C20H24N4O4
CAS Number 155270-99-8
Solubility (25°C) DMSO 20 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] No authors listed. Istradefylline

[2] Peter Jenner, et al. Istradefylline - a first generation adenosine A 2A antagonist for the treatment of Parkinson's disease

[3] D M Paton. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease

[4] Margherita Torti, et al. Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?

[5] Thomas Mller. The safety of istradefylline for the treatment of Parkinson's disease

Related Adenosine Receptor Products
CV1808

CV1808 (2-Phenylaminoadenosine) is a non-selective A2 adenosine receptor (A2 AR) agonist with Kis of 76 and 1450 nM for A2A and A3 adenosine receptor subtypes, respectively.

FK 453 

FK 453 is a potent and selective adenosine A1 receptor antagonist with an IC50 value of 17.2 nM.

GS-9667

GS-9667 (CVT 3619), a novel N6-5'-substituted adenosine analog, is a selective, partial agonist of the A1 adenosine receptor (A1AdoR).

PD81723 

PD81723 is an adenosine receptor binding enhancer.

PSB-0788 

PSB-0788 is a new selective high-affinity A2B antagonist with IC50 value of 3.64 nM and Ki value of 0.393 nM, respeactively.

  Catalog
Abmole Inhibitor Catalog




Keywords: Istradefylline, KW-6002 supplier, Adenosine Receptor, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.